{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-111203","form_type":"8-K","ticker":"BIO","cik":"0000012208","company_name":"BIO-RAD LABORATORIES, INC.","filed_at":"2022-04-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:59.977273+00:00","generated_at":"2026-06-26T06:05:49.694142+00:00","sec_items":["1.01","2.03","9.01"],"event_type":"debt","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"Bio-Rad amends credit agreement to exclude cash over $200M from leverage ratio","bullets":["Amendment No. 2 redefines Leverage Ratio to deduct cash and cash equivalents exceeding $200M from total funded debt.","Section 6.1 reporting deadlines extended: annual financials to 120 days (from 90) and quarterly to 60 days (from 45).","Amendment effective April 15, 2022; no defaults or new borrowing; lenders include JPMorgan, Bank of America, HSBC, and others."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-111203","json":"https://secwatch.observer/filing/0001193125-22-111203.json","markdown":"https://secwatch.observer/filing/0001193125-22-111203.md","text":"https://secwatch.observer/filing/0001193125-22-111203.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/12208/000119312522111203/0001193125-22-111203-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/12208/000119312522111203/d321252d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T06:05:49.694142+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}